Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -52.72% is 57% above its 5-year average of -123.41%, near the high end of its 5-year range (-603.00%–-19.21%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.79% below its 12-month average of -42.59%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -52.72%.
RETURN ON EQUITY (ROE)
-52.72%
RETURN ON EQUITY (ROE) AVG TTM
-42.59%
RETURN ON EQUITY (ROE) AVG 3Y
-109.52%
RETURN ON EQUITY (ROE) AVG 5Y
-123.41%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.79%
CURRENT VS 3Y AVG
+51.86%
CURRENT VS 5Y AVG
+57.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-25.49%
vs the sector median at left
Dogwood Therapeutics, Inc.
Market Cap
$49.94M
Return on Equity (ROE)
-52.72%
TTM Avg
-42.59%
3Y Avg
-109.52%
5Y Avg
-123.41%
Market Cap
$49.58M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
Market Cap
$49.55M
Return on Equity (ROE)
-42.01%
TTM Avg
-2.07%
3Y Avg
11.82%
5Y Avg
5.22%
Market Cap
$49.47M
Return on Equity (ROE)
-17.84%
TTM Avg
-32.49%
3Y Avg
-23.88%
5Y Avg
-18.14%
Market Cap
$49.22M
Return on Equity (ROE)
-23.70%
TTM Avg
-170.56%
3Y Avg
-190.10%
5Y Avg
-146.13%
Market Cap
$49.21M
Return on Equity (ROE)
N/A
TTM Avg
-374.04%
3Y Avg
-326.22%
5Y Avg
-254.86%
Market Cap
$50.56M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$49.93M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$48.82M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $49.94M | -52.72% | -42.59% | -109.52% | -123.41% |
| INmune Bio, Inc. (INMB)vs › | $49.58M | -90.44% | -163.19% | -112.62% | -86.58% |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.55M | -42.01% | -2.07% | 11.82% | 5.22% |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | -17.84% | -32.49% | -23.88% | -18.14% |
| Microbot Medical Inc. (MBOT)vs › | $49.22M | -23.70% | -170.56% | -190.10% | -146.13% |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | -374.04% | -326.22% | -254.86% |
| Envoy Medical, Inc. (COCH)vs › | $50.56M | -708.48% | 156.13% | 510.26% | 342.91% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $49.93M | N/A | 31.64% | 119.26% | -26.51% |
| Apollomics, Inc. (APLM)vs › | $48.82M | N/A | -382.07% | -282.25% | -171.00% |
| Clene Inc. (CLNN)vs › | $50.51M | N/A | 296.81% | -175.08% | -1071.79% |
ROE
-52.7%
ROA
-44.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -52.72% |
| 2026-03-31 | -35.13% |
| 2025-12-31 | -45.74% |
| 2025-09-30 | -49.37% |
| 2025-06-30 | -29.97% |
| 2025-03-31 | -310.20% |
| 2024-12-31 | -19.21% |
| 2024-09-30 | -603.00% |
| 2024-06-30 | -149.22% |
| 2024-03-31 | -191.01% |
| 2023-12-31 | -139.12% |
| 2023-09-30 | -130.99% |
| 2023-06-30 | -161.51% |
| 2023-03-31 | -164.19% |
| 2022-12-31 | -167.17% |
| 2022-09-30 | -159.51% |
| 2022-06-30 | -227.50% |
| 2022-03-31 | -158.02% |
| 2021-12-31 | -110.06% |
| 2021-09-30 | -95.07% |
| 2021-06-30 | -72.46% |
| 2021-03-31 | -47.72% |
| 2020-12-31 | -34.56% |
